Letter to the Editor
Will the Quality of Research Remain the Same During the COVID-19 Pandemic?

https://doi.org/10.1016/j.cgh.2020.03.054Get rights and content

Cited by (0)

Conflicts of interest The author discloses the following: Laurent Peyrin-Biroulet has received personal fees from AbbVie, Janssen, Genentech, Ferring, Tillots, Pharmacosmos, Celltrion, Takeda, Boerhinger Ingelheim, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Alma, Sterna, Nestle, Enterome, Allergan, MSD, Roche, Arena, Gilead, Hikma, Amgen, BMS, Vifor, Norgine, Mylan, Lilly, Fresenius Kabi, Oppilan Pharma, Sublimity Therapeutics, Applied Molecular Transport, OSE Immunotherapeutics, Enthera, and Theravance, grants from AbbVie, MSD, and Takeda, and holds stock options in CTMA.

View Abstract